Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.

Concomitant csDMARD use leads to lower bDMARD discontinuation in RA patients

10 Aug 2019

Concomitant use of conventional synthetic disease-modifying antirheumatic drug (csDMARD) results in a significantly lower risk for discontinuation of biologic (b)DMARD because of adverse events (AEs) among patients with rheumatoid arthritis (RA), according to a recent study.

In addition, neither methotrexate (MTX) route of administration nor dose significantly predicted bDMARD durability.

A total of 814 patients were included, among whom 153 (18.8 percent) received bDMARD monotherapy and 661 (81.2 percent) combination csDMARD/bDMARD therapy. Of the patients, 38.7 percent discontinued bDMARD over a mean follow-up of 1.9 years.

Multivariate analysis revealed a nonsignificant trend toward lower discontinuation for the combination therapy vs monotherapy for any reason (hazard ratio [HR] ,0.76, 95 percent CI, 0.55–1.05) and owing to ineffectiveness/AE (HR, 0.73, 0.50–1.06). Moreover, the risk of bDMARD discontinuation due to AE was significantly lower among patients taking the combination therapy (HR, 0.43, 0.24–0.76).

The secondary analysis showed no statistically significant relationship between MTX dose or route of administration and bDMARD durability.

The study enrolled patients from the Ontario Best Practices Research Initiative who initiated bDMARD therapy and had ≥1 follow-up assessment. Multivariate Cox regression was used to assess the effect of concomitant csDMARD use and MTX route of administration on bDMARD discontinuation due to (1) any reason, (2) ineffectiveness, (3) AEs, or (4) both ineffectiveness and AEs.

“Prior studies have suggested that concurrent csDMARD therapy enhances the efficacy of bDMARD,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.